ALEXANDRIA, Va., July 16 -- United States Patent no. 12,358,992, issued on July 15, was assigned to Scholar Rock Inc. (Cambridge, Mass.).

"LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof" was invented by Thomas Schurpf (Cambridge, Mass.), Christopher Littlefield (Marblehead, Mass.), Gregory J. Carven (Maynard, Mass.) and Abhishek Datta (Boston).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are inhibitors, such as antibodies, and antigen binding portions thereof, that selectively bind complexes of LTBP1-TGFBeta1 and/or LTBP3-TGFBeta1. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFBeta1 activation, and treating subjects sufferi...